We continue to bring together people from across the world to share their experiences of how the coronavirus pandemic has affected their lives. Today we speak to three oncologists - doctors who specialize in cancer care - to hear how cancer treatment and patients have been impacted by the pandemic.

Read more here

NEW YORK (Reuters Health) - In patients with esophageal cancer, post-op complications, but not surgical approach, is an independent predictor of survival, according to European researchers. "The value of this study is that it is the rst to directly identify overall postoperative complications as a negative prognostic and potential mediating factor for survival in a randomized controlled trial comparing minimally invasive- and open surgery," Dr. Frederiek Nuytens of Hopital Claude Huriez, in Lille, France, told Reuters Health by email

Read more here

Researchers have shown in mice that designer antibodies can curb the growth of tumors by targeting two of cancer’s most infamous offenders—the proteins RAS and p53, which are mutated in many tumors but have largely defied drug development efforts. If their promise holds up in clinical trials, such drugs could make it possible to unleash the body’s immune system on hard-to-treat cancers including pancreatic and ovarian.

Read more here